Halyard Health, Inc. (HYH) Receives Consensus Rating of “Buy” from Analysts

Shares of Halyard Health, Inc. (NYSE:HYH) have been given a consensus rating of “Buy” by the nine analysts that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $44.00.

HYH has been the subject of several research analyst reports. TheStreet lowered shares of Halyard Health from a “b-” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research lowered shares of Halyard Health from a “buy” rating to a “sell” rating in a research note on Wednesday, October 4th. KeyCorp restated a “hold” rating on shares of Halyard Health in a research note on Tuesday, October 17th. Deutsche Bank AG raised their price target on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus restated a “buy” rating and set a $45.00 price target on shares of Halyard Health in a research note on Thursday, September 21st.

A number of institutional investors have recently added to or reduced their stakes in HYH. Goldman Sachs Group Inc. grew its stake in Halyard Health by 242.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after buying an additional 1,320,735 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Halyard Health by 19.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after purchasing an additional 507,893 shares during the period. Northern Trust Corp boosted its holdings in Halyard Health by 41.2% in the 2nd quarter. Northern Trust Corp now owns 1,510,297 shares of the medical instruments supplier’s stock valued at $59,324,000 after purchasing an additional 440,639 shares during the period. Macquarie Group Ltd. bought a new position in Halyard Health in the 3rd quarter valued at $19,063,000. Finally, Koch Industries Inc. bought a new position in Halyard Health in the 2nd quarter valued at $297,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Halyard Health (HYH) traded up $0.10 during trading hours on Monday, reaching $45.79. 202,915 shares of the company’s stock traded hands, compared to its average volume of 350,458. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.19 and a current ratio of 2.13. The stock has a market cap of $2,140.00, a price-to-earnings ratio of 21.86, a price-to-earnings-growth ratio of 2.47 and a beta of 1.69. Halyard Health has a 52-week low of $35.24 and a 52-week high of $50.99.

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.13. The firm had revenue of $401.40 million during the quarter, compared to analyst estimates of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $0.48 EPS. analysts expect that Halyard Health will post 2.08 earnings per share for the current year.

WARNING: “Halyard Health, Inc. (HYH) Receives Consensus Rating of “Buy” from Analysts” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2017/12/06/halyard-health-inc-hyh-receives-consensus-rating-of-buy-from-analysts.html.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply